Zevra Therapeutics Inc. (ZVRA) Stock Analysis

Zevra Therapeutics Inc. (ZVRA) is a publicly traded company in the HEALTHCARE sector. It trades at $10.88, carries a market capitalization of $679.23M, a price-to-earnings ratio of 5.72. This page summarizes the public market data, fundamentals, and frequently asked questions for ZVRA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $10.88
• Market Cap: $679.23M
• P/E Ratio: 5.72
• EPS: $2.01
• 52-Week High: $13.16
• 52-Week Low: $7.16

Market Sentiment

Zevra Therapeutics Inc. currently has a Bullish sentiment score of 0.24.

About Zevra Therapeutics Inc.

Zevra Therapeutics, Inc. is a pioneering biopharmaceutical company headquartered in Celebration, Florida, dedicated to addressing unmet medical needs in rare diseases through its advanced prodrug development platform. The company focuses on developing innovative therapies for serious conditions, leveraging proprietary technology to improve drug efficacy and enhance patient outcomes. With a robust pipeline and a strategic commitment to rare disease therapeutics, Zevra Therapeutics is well-posi...

GNG Research Analysis

GNG Research scores Zevra Therapeutics Inc. (ZVRA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ZVRA.

Frequently Asked Questions

Does ZVRA pay dividends?

Zevra Therapeutics Inc. (ZVRA) does not currently pay a regular dividend.

What is ZVRA's P/E ratio?

Zevra Therapeutics Inc. has a price-to-earnings (P/E) ratio of 5.72.

What is ZVRA's market cap?

Zevra Therapeutics Inc. (ZVRA) has a market capitalization of $679.23M with a current stock price of $10.88.